Open AccessEffects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
Author(s) -
Kuhadiya Nitesh D.,
Mahmood Israa
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4022
Subject(s) - medicine , concomitant , glucagon like peptide 1 receptor , agonist , pharmacology , type 2 diabetes , urology , diabetes mellitus , endocrinology , receptor
Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m 2 )